Meiragtx Holdings Plc (MGTX) has released an update.
MeiraGTx Holdings plc has reached a significant milestone by earning $50 million from Janssen Pharmaceuticals, as part of their December 2023 agreement for botaretigene sparoparvovec, a gene therapy treatment for X-linked retinitis pigmentosa. This achievement underscores the company’s progress and potential in the field of medical biotechnology, marking a notable moment for investors watching the innovative therapy’s journey towards commercial success.
For further insights into MGTX stock, check out TipRanks’ Stock Analysis page.
